Literature DB >> 10470576

Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants.

C Romagnoli1, E Zecca, G Vento, M P De Carolis, P Papacci, G Tortorolo.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration.
DESIGN: Randomised clinical trial.
SETTING: Neonatal intensive care unit. PATIENTS: 50 infants at high risk of CLD were randomly assigned after 72 h of life to the dexamethasone group (n = 25) or to the control group (n = 25). The treated infants received dexamethasone intravenously from the 4th day of life for 7 days (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days and 0.125 mg/kg per day on the 7th day). The control group received no steroid treatment.
RESULTS: The incidence of CLD at 28 days of life and at 36 weeks' postconceptional age was significantly lower in the dexamethasone group than in the control group (p < 0.001). Moreover, infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (p < 0.001). Hyperglycaemia, hypertension, growth failure and mainly hypertrophy of the left ventricle were the transient side effects associated with early steroid administration.
CONCLUSIONS: Early dexamethasone administration may be useful in preventing CLD, but its use should prudently be restricted to preterm infants at high risk of CLD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470576     DOI: 10.1007/s001340050935

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

Review 1.  Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Susanne Hay; Brett J Manley; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2021-11-11

Review 2.  Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Susanne Hay; Brett J Manley; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2021-10-21

Review 3.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24

4.  Early prophylactic inhaled beclomethasone in infants less than 1250 g for the prevention of chronic lung disease.

Authors:  K A Jangaard; D A Stinson; A C Allen; M J Vincer
Journal:  Paediatr Child Health       Date:  2002-01       Impact factor: 2.253

5.  Adrenocortical function and chronic lung disease of pre-maturity: an unresolved problem?

Authors:  C Romagnoli; C Latella; E Zecca; P Papacci; G Tortorolo
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

6.  Evidence-Based Neonatal Unit Practices and Determinants of Postnatal Corticosteroid-Use in Preterm Births below 30 Weeks GA in Europe. A Population-Based Cohort Study.

Authors:  Alexandra Nuytten; Hélène Behal; Alain Duhamel; Pierre-Henri Jarreau; Jan Mazela; David Milligan; Ludwig Gortner; Aurélie Piedvache; Jennifer Zeitlin; Patrick Truffert
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

7.  Effect of dexamethasone on the IGFBP-1 regulation in premature infants during the first weeks of life.

Authors:  Axel Dost; Eberhard Kauf; Dorothea Schlenvoigt; Dirk Schramm; Felix Zintl; Axel Hübler
Journal:  Biologics       Date:  2007-12

8.  Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

Authors:  Viraraghavan Vadakkencherry Ramaswamy; Tapas Bandyopadhyay; Debasish Nanda; Prathik Bandiya; Javed Ahmed; Anip Garg; Charles C Roehr; Sushma Nangia
Journal:  JAMA Pediatr       Date:  2021-06-07       Impact factor: 16.193

Review 9.  A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.

Authors:  K S Beam; S Aliaga; S K Ahlfeld; M Cohen-Wolkowiez; P B Smith; M M Laughon
Journal:  J Perinatol       Date:  2014-07-10       Impact factor: 3.225

10.  Efficacy of glucocorticoids, vitamin A and caffeine therapies for neonatal mortality in preterm infants: a network meta-analysis.

Authors:  Ying Li; Jie Gao; Qiwei Wang; Xiaojian Ma
Journal:  Oncotarget       Date:  2017-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.